Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | PGK1 | P00558 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | WDR5 | P61964 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
| ▸ | ACLY | P53396 | 1/20 | 0.30 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.30 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23958833 | 0.78 | HRH4 (0.36) | HRH4ALDH1A1CYP3A4SIGMAR1MAOA | |
| SCHEMBL3720608 | 0.78 | WDR5 (0.41) | PGK1ALDH1A1CYP3A4WDR5ACLY | |
| SCHEMBL23930187 | 0.78 | HRH4 (0.33) | HRH4CA1CA2CA9SIGMAR1 | |
| SCHEMBL4183063 | 0.75 | CYP3A4 (0.33) | PGK1ALDH1A1CYP3A4SLC1A5 | |
| SCHEMBL3716943 | 0.75 | ALDH1A1 (0.34) | PGK1ALDH1A1CYP3A4WDR5GRIN2B | |
| SCHEMBL13515990 | 0.75 | CYP1A2 (0.31) | CYP3A4 | |
| SCHEMBL27801325 | 0.75 | MAPT (0.48) | ALDH1A1CYP3A4 | |
| SCHEMBL31506852 | 0.75 | MAPT (0.48) | ALDH1A1CYP3A4 | |
| SCHEMBL22749548 | 0.74 | GAA (0.32) | GRIN2BCA1CA2CA9 | |
| SCHEMBL26231908 | 0.74 | WDR5 (0.35) | PGK1WDR5ACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993593-B2 | N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2015-03-31 | — | — | US | disclosed |
| US-8580968-B2 | Benzothiazole and benzooxazole derivatives and methods of use | ABBVIE INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580968-B2 | Benzothiazole and benzooxazole derivatives and methods of use | ABBVIE INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580968-B2 | Benzothiazole and benzooxazole derivatives and methods of use | ABBVIE INC. (US) | 2013-11-12 | — | — | US | disclosed |
| EP-2061465-B1 | DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANILIDES AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INT (US) | 2013-04-10 | — | — | EP | disclosed |
| CN-102869250-A | 4- (N-azacycloalkyl) anilide derivatives as potassium channel modulators | VALEANT PHARMACEUTICALS INT | 2013-01-09 | — | — | CN | disclosed |
| EP-2531024-A1 | DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANIILIDES AS POTASSIUM CHANNEL MODULATORS | Valeant Pharmaceuticals International (US) | 2012-12-12 | — | — | EP | disclosed |
| US-8293911-B2 | Seizure disorders; antiepileptic agents; N-(2-chloro-4-(3,4-dihydroisoquinolin-2(1H)-yl)-6-(trifluoromethyl)phenyl)-3,3-dimethylbutanamide for example | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2012-10-23 | — | — | US | disclosed |
| US-20120164070-A1 | BENZOTHIAZOLE AND BENZOOXAZOLE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120164070-A1 | BENZOTHIAZOLE AND BENZOOXAZOLE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2012-06-28 | — | — | US | disclosed |
| WO-2011094186-A1 | DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANIILIDES AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2011-08-04 | — | — | WO | disclosed |
| US-20110003850-A1 | DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANILIDES AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| CN-101563085-A | Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators | VERNIER JEAN MICHEL (US) | 2009-10-21 | — | — | CN | disclosed |
| WO-2009085945-A1 | BENZOTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2009-07-09 | — | — | WO | disclosed |
| US-20090163464-A1 | BENZOTHIAZOLE AND BENZOOXAZOLE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2009-06-25 | — | — | US | disclosed |
| US-20090163464-A1 | BENZOTHIAZOLE AND BENZOOXAZOLE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2009-06-25 | — | — | US | disclosed |
| US-20090163464-A1 | BENZOTHIAZOLE AND BENZOOXAZOLE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2009-06-25 | — | — | US | disclosed |
| EP-2061465-A2 | DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANILIDES AS POTASSIUM CHANNEL MODULATORS | Valeant Pharmaceuticals International (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20080139610-A1 | Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators | VALEANT PHARMACEUTICALS NORTH AMERICA (US) | 2008-06-12 | — | — | US | disclosed |
| WO-2008024398-A2 | DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANILIDES AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003850-A1 | DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANILIDES AS POTASSIUM CHANNEL MODULATORS | KCNQ2, KCNQ1, KCNQ5 | HRH4 2935/4885PGK1 3134/4885ALDH1A1 987/4885 |
| US-20080139610-A1 | Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators | KCNQ2, KCNQ1, KCNQ5 | HRH4 2711/4885PGK1 2998/4885ALDH1A1 1126/4885 |
| US-20120164070-A1 | BENZOTHIAZOLE AND BENZOOXAZOLE DERIVATIVES AND METHODS OF USE | HRH2, HRH1, HRH4 | HRH4 3/4885PGK1 2441/4885ALDH1A1 738/4885 |
| US-20090163464-A1 | BENZOTHIAZOLE AND BENZOOXAZOLE DERIVATIVES AND METHODS OF USE | HRH2, HRH1, HRH4 | HRH4 3/4885PGK1 2441/4885ALDH1A1 738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.